title: Investigating the barriers to bioavailability of macrolide antibiotics in the rat.
abstract: The aim of this study was to compare the roles of gastrointestinal absorption and hepatic extraction as barriers to oral bioavailability for macrolide antibiotics erythromycin, clarithromycin, roxithromycin and telithromycin. In this study, the in vitro metabolic stability in rat liver microsomes and hepatocytes, as well as the in vivo pharmacokinetics in rats were determined following intravenous, intraportal, oral and intraduodenal routes of administration. Pharmacokinetic parameters were calculated for each compound for each route of administration. In vitro metabolic stability studies point to low intrinsic clearance of the tested macrolides in both microsomes (<1 mL/min/g) and hepatocytes (<1 mL/min/g), indicating good stability. The oral bioavailability in rat was low to moderate (14, 36, 36 and 25% for erythromycin, clarithromycin, roxithromycin and telithromycin, respectively). Upon intraduodenal dosing, the bioavailability increased by 1.3-3-fold, the highest increase being with roxithromycin, suggesting some loss due to gastric instability. Following portal vein administration, no hepatic first pass effect was observed with roxithromycin, less than 10% with telithromycin, and ca. 20 and 25% for clarithromycin and erythromycin. Our data showed that the tested macrolides display good in vitro metabolic stability, as was confirmed in vivo where a low hepatic first pass effect was observed. The limited oral bioavailability is likely due to poor oral absorption and/or intestinal first pass metabolism.
authors: GlaxoSmithKline Research Centre Zagreb Ltd, Prilaz baruna Filipovića 29, 10000 Zagreb, Croatia. Jasna.Padovan@glpg.com
authors: Jasna
authors: J
authors: Padovan
authors: Jovica
authors: J
authors: Ralić
authors: Vatroslav
authors: V
authors: Letfus
authors: Astrid
authors: A
authors: Milić
authors: Vlatka
authors: V
authors: Bencetić Mihaljević
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001682:Biological Availability; D017291:Clarithromycin / Q000493:pharmacokinetics; D004917:Erythromycin / Q000493:pharmacokinetics; D022781:Hepatocytes / Q000378:metabolism; D048628:Ketolides / Q000493:pharmacokinetics; D018942:Macrolides / Q000008:administration & dosage / Q000493:pharmacokinetics*; D008297:Male; D008862:Microsomes, Liver / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D015575:Roxithromycin / Q000493:pharmacokinetics
chemical_list: D000900:Anti-Bacterial Agents; D048628:Ketolides; D018942:Macrolides; D015575:Roxithromycin; D004917:Erythromycin; D017291:Clarithromycin; C106791:telithromycin